Drugs in Dev. Oncology
Phase I
Poland 
Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)
Details : RVU120 is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndromes.
Product Name : RVU120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2023
Details : RVU120 (SEL120) is a clinical-stage, highly specific, and orally bioavailable dual inhibitor of CDK8/CDK19 kinases, which has demonstrated efficacy in a number of solid tumor in vitro and in vivo models as well as in hematologic malignancies.
Product Name : RVU120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at EHA 2021
Details : RVU120 (SEL120) is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors.
Product Name : RVU120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2021
Details : RVU120 (SEL120) is a highly selective first-in-class CDK8/CDK19 inhibitor, which has demonstrated efficacy in a number of solid tumor types in in vitro and in vivo models as well as in onco-hematological malignancies.
Product Name : RVU120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2021
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas.
Product Name : RTA 744
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 27, 2021
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ryvu Therapeutics to Receive NCRD Grant to Develop Targeted Immuno-Oncology Therapy
Details : This grant Supports Ryvu to develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches.
Product Name : RVU120
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 06, 2020
Details : SEL120 has shown strong proof of concept in the preclinical studies and has received a strategic support from The Leukemia & Lymphoma Society (LLS) through its Therapy Acceleration Program.
Product Name : SEL120
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2020
Details : WP1066 drug candidate received FDA approval for Investigational New Drug status to be used in a Phase 1 clinical trial for recurrent or refractory malignant brain tumors in children.
Product Name : WP1066
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2020
Reset All
